Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.

Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.

Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether 18F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant gliomas in the...

Full description

Bibliographic Details
Main Authors: Shigeru Yamaguchi, Kenji Hirata, Takuya Toyonaga, Kentaro Kobayashi, Yukitomo Ishi, Hiroaki Motegi, Hiroyuki Kobayashi, Tohru Shiga, Nagara Tamaki, Shunsuke Terasaka, Kiyohiro Houkin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5148016?pdf=render

Internet

http://europepmc.org/articles/PMC5148016?pdf=render

Similar Items